Abstract
Pioglitazone [‘Actos’], a new thiazolidinedione derivative, improves glycaemic control and lipid profiles in patients with type 2 diabetes mellitus when used as monotherapy or in combination treatment. A trial of once-daily pioglitazone monotherapy showed significant improvement in glycosylated haemoglobin (HbA 1c ) and fasting blood glucose levels, and the degree of improvement was dose-related. Other studies showed that pioglitazone in combination with metformin or a sulfonylurea improved glycaemic control in patients with type 2 diabetes who were poorly controlled on monotherapy. The patients were also dyslipidaemic, and the studies showed a consistent pattern of improvement in lipid profile, characterised by a decline in triglyceride levels and an increase in HDL-cholesterol levels. Importantly, pioglitazone has not been associated with hepatotoxicity. The studies were presented at the 59th Annual Meeting of the American Diabetes Association [ San Diego, US; June, 1999 ].
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
